Ellen Burnham
Concepts (547)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Alcoholism | 38 | 2025 | 805 | 6.780 |
Why?
| | Bronchoalveolar Lavage Fluid | 22 | 2022 | 654 | 2.020 |
Why?
| | Respiratory Insufficiency | 10 | 2025 | 316 | 2.010 |
Why?
| | Lung | 19 | 2025 | 4066 | 1.800 |
Why?
| | Alcohol-Related Disorders | 7 | 2015 | 124 | 1.700 |
Why?
| | Cannabis | 5 | 2025 | 490 | 1.360 |
Why?
| | Pneumonia | 9 | 2023 | 638 | 1.340 |
Why?
| | Ethanol | 11 | 2022 | 608 | 1.320 |
Why?
| | Acute Lung Injury | 10 | 2022 | 288 | 1.320 |
Why?
| | Respiratory Mucosa | 4 | 2020 | 324 | 1.270 |
Why?
| | Critical Illness | 21 | 2024 | 809 | 1.230 |
Why?
| | Intensive Care Units | 19 | 2025 | 803 | 1.220 |
Why?
| | Marijuana Smoking | 3 | 2025 | 250 | 1.140 |
Why?
| | Sepsis | 6 | 2020 | 611 | 1.100 |
Why?
| | Gene Expression | 3 | 2020 | 1505 | 1.050 |
Why?
| | Macrophages, Alveolar | 9 | 2021 | 392 | 1.030 |
Why?
| | Critical Care | 10 | 2021 | 584 | 1.020 |
Why?
| | Cytokines | 9 | 2025 | 2095 | 0.980 |
Why?
| | Survivors | 8 | 2025 | 489 | 0.930 |
Why?
| | Middle Aged | 71 | 2025 | 33355 | 0.910 |
Why?
| | Inflammation Mediators | 4 | 2016 | 514 | 0.900 |
Why?
| | Central Nervous System Depressants | 2 | 2021 | 85 | 0.860 |
Why?
| | Noninvasive Ventilation | 2 | 2024 | 51 | 0.860 |
Why?
| | Pulmonary Alveoli | 6 | 2016 | 405 | 0.850 |
Why?
| | Acetates | 2 | 2021 | 100 | 0.840 |
Why?
| | Stem Cells | 5 | 2015 | 589 | 0.820 |
Why?
| | Streptococcus pneumoniae | 2 | 2018 | 169 | 0.820 |
Why?
| | Adult | 65 | 2025 | 37821 | 0.810 |
Why?
| | Pulmonary Fibrosis | 3 | 2022 | 400 | 0.800 |
Why?
| | Mentors | 4 | 2014 | 197 | 0.790 |
Why?
| | Substance Withdrawal Syndrome | 4 | 2021 | 179 | 0.790 |
Why?
| | Humans | 129 | 2025 | 137514 | 0.780 |
Why?
| | Leukocytes, Mononuclear | 3 | 2017 | 558 | 0.770 |
Why?
| | Lung Diseases | 3 | 2021 | 768 | 0.770 |
Why?
| | Smoking | 8 | 2021 | 1639 | 0.760 |
Why?
| | Hospital Mortality | 6 | 2020 | 902 | 0.750 |
Why?
| | Cerebrovascular Circulation | 2 | 2021 | 242 | 0.750 |
Why?
| | Male | 79 | 2025 | 67718 | 0.700 |
Why?
| | Hospitalization | 9 | 2023 | 2197 | 0.700 |
Why?
| | Female | 81 | 2025 | 73162 | 0.700 |
Why?
| | Behavior | 1 | 2021 | 95 | 0.690 |
Why?
| | Respiration, Artificial | 13 | 2025 | 643 | 0.690 |
Why?
| | Thalamus | 2 | 2021 | 110 | 0.680 |
Why?
| | Hypnotics and Sedatives | 4 | 2025 | 199 | 0.680 |
Why?
| | Glycerophospholipids | 4 | 2024 | 34 | 0.680 |
Why?
| | Case-Control Studies | 14 | 2022 | 3546 | 0.670 |
Why?
| | Burnout, Professional | 4 | 2022 | 442 | 0.650 |
Why?
| | Hallucinogens | 1 | 2021 | 105 | 0.630 |
Why?
| | Cigarette Smoking | 2 | 2020 | 102 | 0.610 |
Why?
| | Glutathione | 5 | 2016 | 358 | 0.590 |
Why?
| | RNA, Messenger | 5 | 2020 | 2838 | 0.590 |
Why?
| | Opioid-Related Disorders | 2 | 2023 | 510 | 0.590 |
Why?
| | Antioxidants | 4 | 2016 | 577 | 0.580 |
Why?
| | Intubation, Intratracheal | 1 | 2020 | 259 | 0.580 |
Why?
| | Pneumonia, Pneumococcal | 1 | 2018 | 48 | 0.580 |
Why?
| | Toll-Like Receptor 2 | 2 | 2016 | 117 | 0.570 |
Why?
| | Epithelial Cells | 4 | 2021 | 1099 | 0.560 |
Why?
| | Physicians, Women | 1 | 2019 | 83 | 0.560 |
Why?
| | Xanthine Dehydrogenase | 1 | 2017 | 25 | 0.560 |
Why?
| | Inflammation | 8 | 2025 | 2837 | 0.560 |
Why?
| | Tobacco Products | 1 | 2019 | 142 | 0.550 |
Why?
| | Bronchoalveolar Lavage | 7 | 2023 | 93 | 0.540 |
Why?
| | Biomedical Research | 2 | 2021 | 689 | 0.520 |
Why?
| | Toll-Like Receptor 4 | 2 | 2016 | 274 | 0.510 |
Why?
| | Blood-Air Barrier | 2 | 2008 | 11 | 0.510 |
Why?
| | Organ Dysfunction Scores | 1 | 2016 | 47 | 0.510 |
Why?
| | Alcohol Drinking | 6 | 2025 | 824 | 0.490 |
Why?
| | Marijuana Abuse | 1 | 2018 | 234 | 0.490 |
Why?
| | Burns | 4 | 2024 | 323 | 0.490 |
Why?
| | Azithromycin | 1 | 2015 | 94 | 0.470 |
Why?
| | Tomography | 2 | 2025 | 40 | 0.460 |
Why?
| | Electric Impedance | 2 | 2025 | 109 | 0.450 |
Why?
| | Pulmonary Disease, Chronic Obstructive | 2 | 2019 | 1042 | 0.430 |
Why?
| | Professional Autonomy | 1 | 2013 | 30 | 0.430 |
Why?
| | Radiography, Thoracic | 1 | 2014 | 168 | 0.420 |
Why?
| | Research Support as Topic | 2 | 2011 | 118 | 0.420 |
Why?
| | Tomography, X-Ray Computed | 2 | 2014 | 2681 | 0.420 |
Why?
| | Cells, Cultured | 8 | 2018 | 4206 | 0.410 |
Why?
| | Aged | 32 | 2025 | 23798 | 0.410 |
Why?
| | Lipopolysaccharides | 5 | 2017 | 886 | 0.410 |
Why?
| | Bronchoscopy | 3 | 2023 | 222 | 0.400 |
Why?
| | Oxidative Stress | 5 | 2017 | 1307 | 0.400 |
Why?
| | Immunity, Innate | 1 | 2018 | 832 | 0.390 |
Why?
| | Retrospective Studies | 22 | 2025 | 15628 | 0.380 |
Why?
| | Drugs, Chinese Herbal | 1 | 2012 | 21 | 0.380 |
Why?
| | Academic Medical Centers | 2 | 2014 | 498 | 0.370 |
Why?
| | Intensive Care Units, Pediatric | 1 | 2013 | 233 | 0.370 |
Why?
| | Venous Thromboembolism | 3 | 2020 | 313 | 0.350 |
Why?
| | Imaging, Three-Dimensional | 2 | 2025 | 581 | 0.350 |
Why?
| | Asthma | 2 | 2022 | 2290 | 0.350 |
Why?
| | Biomarkers | 14 | 2024 | 4172 | 0.340 |
Why?
| | Gene Expression Regulation | 6 | 2022 | 2615 | 0.340 |
Why?
| | Personnel Selection | 1 | 2011 | 78 | 0.330 |
Why?
| | Lymphoid Progenitor Cells | 1 | 2009 | 11 | 0.330 |
Why?
| | Malondialdehyde | 2 | 2021 | 29 | 0.320 |
Why?
| | Acetaldehyde | 2 | 2021 | 17 | 0.320 |
Why?
| | Personnel Staffing and Scheduling | 1 | 2010 | 94 | 0.320 |
Why?
| | Medical Staff, Hospital | 1 | 2010 | 83 | 0.320 |
Why?
| | Muscular Diseases | 3 | 2017 | 115 | 0.320 |
Why?
| | Anti-Bacterial Agents | 2 | 2019 | 1800 | 0.310 |
Why?
| | Pneumococcal Infections | 1 | 2010 | 116 | 0.310 |
Why?
| | Cohort Studies | 13 | 2020 | 5730 | 0.310 |
Why?
| | Multiple Organ Failure | 3 | 2006 | 127 | 0.300 |
Why?
| | Smokers | 2 | 2021 | 148 | 0.300 |
Why?
| | Hypoxia | 3 | 2025 | 1108 | 0.290 |
Why?
| | Epidemics | 2 | 2019 | 87 | 0.280 |
Why?
| | Pulmonary Embolism | 3 | 2019 | 222 | 0.280 |
Why?
| | Burns, Inhalation | 2 | 2017 | 9 | 0.280 |
Why?
| | Airway Extubation | 3 | 2013 | 57 | 0.280 |
Why?
| | Sexism | 2 | 2019 | 62 | 0.280 |
Why?
| | Betacoronavirus | 2 | 2020 | 268 | 0.270 |
Why?
| | Benzodiazepines | 2 | 2025 | 153 | 0.270 |
Why?
| | Pilot Projects | 6 | 2025 | 1703 | 0.270 |
Why?
| | Anesthesiology | 1 | 2008 | 85 | 0.270 |
Why?
| | Alcohol-Induced Disorders, Nervous System | 1 | 2006 | 6 | 0.270 |
Why?
| | Toll-Like Receptors | 2 | 2018 | 186 | 0.270 |
Why?
| | Endothelial Cells | 4 | 2011 | 780 | 0.270 |
Why?
| | Tissue Plasminogen Activator | 2 | 2018 | 225 | 0.260 |
Why?
| | Tumor Necrosis Factor-alpha | 4 | 2018 | 1242 | 0.260 |
Why?
| | Multivariate Analysis | 5 | 2023 | 1524 | 0.260 |
Why?
| | Deglutition Disorders | 3 | 2013 | 143 | 0.260 |
Why?
| | Fibronectins | 1 | 2007 | 133 | 0.260 |
Why?
| | APACHE | 4 | 2013 | 69 | 0.250 |
Why?
| | Young Adult | 13 | 2024 | 13243 | 0.250 |
Why?
| | Marijuana Use | 2 | 2022 | 203 | 0.250 |
Why?
| | Preoperative Care | 1 | 2008 | 356 | 0.250 |
Why?
| | NLR Family, Pyrin Domain-Containing 3 Protein | 2 | 2017 | 151 | 0.250 |
Why?
| | Risk Factors | 16 | 2020 | 10356 | 0.240 |
Why?
| | Immunity, Cellular | 2 | 2018 | 268 | 0.240 |
Why?
| | Attitude of Health Personnel | 1 | 2013 | 1169 | 0.240 |
Why?
| | Polyunsaturated Alkamides | 1 | 2025 | 8 | 0.240 |
Why?
| | Administration, Inhalation | 3 | 2025 | 683 | 0.240 |
Why?
| | Tobacco Use Cessation | 1 | 2025 | 26 | 0.240 |
Why?
| | Pediatrics | 1 | 2013 | 1123 | 0.240 |
Why?
| | Nutritional Physiological Phenomena | 1 | 2005 | 54 | 0.240 |
Why?
| | Pneumonia, Viral | 2 | 2020 | 368 | 0.240 |
Why?
| | Neuromuscular Blockade | 1 | 2025 | 31 | 0.240 |
Why?
| | Coronavirus Infections | 2 | 2020 | 359 | 0.230 |
Why?
| | Arachidonic Acids | 1 | 2025 | 62 | 0.230 |
Why?
| | Flow Cytometry | 2 | 2024 | 1185 | 0.230 |
Why?
| | Propofol | 1 | 2025 | 73 | 0.230 |
Why?
| | Endocannabinoids | 1 | 2025 | 63 | 0.220 |
Why?
| | United States | 15 | 2025 | 14696 | 0.220 |
Why?
| | Immunity | 1 | 2025 | 145 | 0.220 |
Why?
| | Dysbiosis | 2 | 2024 | 180 | 0.220 |
Why?
| | Patient Acceptance of Health Care | 3 | 2019 | 809 | 0.220 |
Why?
| | E-Selectin | 1 | 2004 | 58 | 0.220 |
Why?
| | Quality of Life | 2 | 2013 | 2870 | 0.220 |
Why?
| | Bacterial Proteins | 1 | 2010 | 889 | 0.220 |
Why?
| | Anticoagulants | 2 | 2019 | 665 | 0.210 |
Why?
| | Patient Discharge | 3 | 2024 | 895 | 0.210 |
Why?
| | Aged, 80 and over | 10 | 2022 | 7593 | 0.210 |
Why?
| | Internship and Residency | 1 | 2013 | 1131 | 0.210 |
Why?
| | Immunophenotyping | 1 | 2024 | 321 | 0.210 |
Why?
| | Interleukin-1beta | 2 | 2017 | 373 | 0.210 |
Why?
| | Shock, Septic | 2 | 2022 | 221 | 0.200 |
Why?
| | Lung Injury | 2 | 2016 | 218 | 0.200 |
Why?
| | Polyneuropathies | 2 | 2017 | 55 | 0.200 |
Why?
| | Dyspnea | 2 | 2019 | 251 | 0.200 |
Why?
| | Interferons | 2 | 2016 | 199 | 0.200 |
Why?
| | Receptor-Like Protein Tyrosine Phosphatases, Class 4 | 1 | 2022 | 23 | 0.190 |
Why?
| | Epithelium | 2 | 2021 | 315 | 0.190 |
Why?
| | Smoke Inhalation Injury | 2 | 2012 | 28 | 0.190 |
Why?
| | Fibroblasts | 3 | 2013 | 990 | 0.190 |
Why?
| | Age Factors | 4 | 2021 | 3301 | 0.180 |
Why?
| | Delirium | 1 | 2023 | 85 | 0.180 |
Why?
| | Double-Blind Method | 4 | 2014 | 1987 | 0.180 |
Why?
| | Interleukin-8 | 3 | 2018 | 269 | 0.180 |
Why?
| | Alcohol Abstinence | 1 | 2021 | 12 | 0.180 |
Why?
| | Societies, Medical | 2 | 2025 | 820 | 0.180 |
Why?
| | Smoking Cessation | 1 | 2025 | 447 | 0.180 |
Why?
| | Cell Count | 2 | 2015 | 321 | 0.180 |
Why?
| | Critical Care Outcomes | 1 | 2020 | 12 | 0.180 |
Why?
| | Status Asthmaticus | 1 | 2020 | 11 | 0.180 |
Why?
| | Neutrophils | 3 | 2017 | 1238 | 0.170 |
Why?
| | Feces | 1 | 2024 | 479 | 0.170 |
Why?
| | Physicians | 3 | 2022 | 904 | 0.170 |
Why?
| | Random Allocation | 1 | 2021 | 357 | 0.170 |
Why?
| | Pandemics | 4 | 2022 | 1619 | 0.170 |
Why?
| | Phagocytosis | 2 | 2014 | 379 | 0.170 |
Why?
| | Analgesics, Opioid | 2 | 2025 | 1002 | 0.170 |
Why?
| | Real-Time Polymerase Chain Reaction | 2 | 2018 | 344 | 0.160 |
Why?
| | Animals | 18 | 2025 | 37011 | 0.160 |
Why?
| | Comorbidity | 4 | 2020 | 1618 | 0.160 |
Why?
| | Permeability | 2 | 2012 | 162 | 0.160 |
Why?
| | Capacity Building | 1 | 2020 | 62 | 0.160 |
Why?
| | Immunoglobulin A | 1 | 2021 | 210 | 0.160 |
Why?
| | Career Choice | 2 | 2012 | 215 | 0.160 |
Why?
| | Wounds and Injuries | 1 | 2006 | 752 | 0.160 |
Why?
| | Chemokines | 2 | 2018 | 229 | 0.160 |
Why?
| | von Willebrand Factor | 1 | 2019 | 81 | 0.160 |
Why?
| | Cardiology | 1 | 2022 | 279 | 0.160 |
Why?
| | Homeostasis | 1 | 2003 | 622 | 0.160 |
Why?
| | Disaster Planning | 1 | 2020 | 89 | 0.160 |
Why?
| | Needs Assessment | 1 | 2021 | 368 | 0.150 |
Why?
| | Speech Therapy | 1 | 2019 | 21 | 0.150 |
Why?
| | Extracorporeal Membrane Oxygenation | 1 | 2022 | 292 | 0.150 |
Why?
| | Faculty, Medical | 1 | 2022 | 283 | 0.150 |
Why?
| | Heparin, Low-Molecular-Weight | 1 | 2018 | 34 | 0.150 |
Why?
| | Pyridines | 2 | 2010 | 508 | 0.150 |
Why?
| | Endothelium, Vascular | 1 | 2005 | 923 | 0.150 |
Why?
| | Macrolides | 1 | 2019 | 63 | 0.150 |
Why?
| | Vecuronium Bromide | 1 | 2018 | 6 | 0.150 |
Why?
| | Statistics, Nonparametric | 4 | 2014 | 434 | 0.150 |
Why?
| | Atracurium | 1 | 2018 | 14 | 0.150 |
Why?
| | Length of Stay | 4 | 2020 | 1210 | 0.150 |
Why?
| | Brain | 3 | 2021 | 2831 | 0.150 |
Why?
| | Heart Failure, Diastolic | 1 | 2018 | 21 | 0.150 |
Why?
| | Heart Failure, Systolic | 1 | 2018 | 25 | 0.140 |
Why?
| | Community-Acquired Infections | 1 | 2020 | 172 | 0.140 |
Why?
| | Pulmonary Ventilation | 1 | 2018 | 79 | 0.140 |
Why?
| | Neuromuscular Blocking Agents | 1 | 2018 | 25 | 0.140 |
Why?
| | Decision Making | 1 | 2025 | 906 | 0.140 |
Why?
| | Cardiologists | 1 | 2018 | 46 | 0.140 |
Why?
| | Apoptosis | 3 | 2014 | 2557 | 0.140 |
Why?
| | Hospitals, University | 2 | 2015 | 181 | 0.140 |
Why?
| | Pyrazoles | 1 | 2001 | 427 | 0.140 |
Why?
| | Occupational Therapy | 1 | 2019 | 99 | 0.140 |
Why?
| | Chemokine CCL2 | 1 | 2017 | 117 | 0.140 |
Why?
| | Heparin | 1 | 2019 | 259 | 0.140 |
Why?
| | Factor Xa Inhibitors | 1 | 2018 | 171 | 0.130 |
Why?
| | Interleukin-1 | 1 | 2001 | 963 | 0.130 |
Why?
| | Tobacco Use | 1 | 2017 | 66 | 0.130 |
Why?
| | Reverse Transcriptase Polymerase Chain Reaction | 2 | 2010 | 974 | 0.130 |
Why?
| | Cystine | 1 | 2016 | 18 | 0.130 |
Why?
| | Transforming Growth Factor beta | 3 | 2022 | 480 | 0.130 |
Why?
| | Cyclooxygenase 2 | 1 | 2017 | 178 | 0.130 |
Why?
| | Interleukin-10 | 1 | 2018 | 302 | 0.130 |
Why?
| | Practice Patterns, Physicians' | 1 | 2025 | 1312 | 0.130 |
Why?
| | Vascular Endothelial Growth Factor A | 3 | 2016 | 544 | 0.130 |
Why?
| | Treatment Outcome | 9 | 2022 | 10821 | 0.130 |
Why?
| | Interleukin-6 | 2 | 2018 | 778 | 0.130 |
Why?
| | Disease Models, Animal | 4 | 2021 | 4295 | 0.130 |
Why?
| | Disulfides | 1 | 2016 | 107 | 0.130 |
Why?
| | Teichoic Acids | 1 | 2016 | 14 | 0.130 |
Why?
| | Gastrointestinal Microbiome | 1 | 2024 | 696 | 0.130 |
Why?
| | Hospitalists | 1 | 2020 | 245 | 0.120 |
Why?
| | Follow-Up Studies | 3 | 2014 | 5139 | 0.120 |
Why?
| | DNA, Bacterial | 1 | 2017 | 336 | 0.120 |
Why?
| | Physical Therapy Modalities | 1 | 2019 | 309 | 0.120 |
Why?
| | Immunosuppressive Agents | 1 | 2001 | 891 | 0.120 |
Why?
| | Fibrinolytic Agents | 1 | 2018 | 275 | 0.120 |
Why?
| | RNA Splicing | 1 | 2017 | 268 | 0.120 |
Why?
| | Respiratory Tract Diseases | 1 | 2017 | 187 | 0.120 |
Why?
| | Inflammasomes | 1 | 2017 | 128 | 0.120 |
Why?
| | Proteins | 2 | 2021 | 1012 | 0.120 |
Why?
| | Alternative Splicing | 1 | 2017 | 227 | 0.120 |
Why?
| | Patient Selection | 2 | 2023 | 691 | 0.120 |
Why?
| | Prevalence | 2 | 2015 | 2719 | 0.120 |
Why?
| | Hospitals | 1 | 2020 | 678 | 0.120 |
Why?
| | Receptors, Antigen, T-Cell, gamma-delta | 1 | 2015 | 101 | 0.120 |
Why?
| | Cysteine | 1 | 2016 | 206 | 0.120 |
Why?
| | Cannabinoids | 1 | 2017 | 161 | 0.120 |
Why?
| | Urinary Bladder | 1 | 2017 | 185 | 0.120 |
Why?
| | Acetylcysteine | 1 | 2016 | 147 | 0.120 |
Why?
| | Idiopathic Pulmonary Fibrosis | 1 | 2022 | 653 | 0.120 |
Why?
| | Cholesterol | 1 | 2017 | 413 | 0.110 |
Why?
| | Interprofessional Relations | 1 | 2017 | 280 | 0.110 |
Why?
| | Signal Transduction | 3 | 2022 | 5096 | 0.110 |
Why?
| | Granulocyte-Macrophage Colony-Stimulating Factor | 2 | 2012 | 152 | 0.110 |
Why?
| | Oxidation-Reduction | 2 | 2016 | 1059 | 0.110 |
Why?
| | Third-Party Consent | 1 | 2013 | 8 | 0.110 |
Why?
| | Severity of Illness Index | 5 | 2016 | 2838 | 0.110 |
Why?
| | Transcriptome | 1 | 2020 | 974 | 0.110 |
Why?
| | Combined Modality Therapy | 1 | 2017 | 1241 | 0.110 |
Why?
| | Serotonin Plasma Membrane Transport Proteins | 1 | 2014 | 77 | 0.110 |
Why?
| | Competency-Based Education | 1 | 2014 | 74 | 0.100 |
Why?
| | Professional Competence | 1 | 2014 | 100 | 0.100 |
Why?
| | Chemokine CCL5 | 1 | 2013 | 43 | 0.100 |
Why?
| | Total Lung Capacity | 1 | 2013 | 33 | 0.100 |
Why?
| | T-Lymphocyte Subsets | 1 | 2015 | 425 | 0.100 |
Why?
| | Growth Differentiation Factor 15 | 1 | 2013 | 41 | 0.100 |
Why?
| | Reproducibility of Results | 3 | 2019 | 3292 | 0.100 |
Why?
| | Quality Improvement | 1 | 2021 | 1161 | 0.100 |
Why?
| | Aging | 2 | 2017 | 1866 | 0.100 |
Why?
| | Pulmonary Diffusing Capacity | 1 | 2013 | 75 | 0.100 |
Why?
| | Disease Progression | 1 | 2020 | 2755 | 0.100 |
Why?
| | Financial Support | 1 | 2012 | 23 | 0.100 |
Why?
| | Speech-Language Pathology | 1 | 2012 | 25 | 0.100 |
Why?
| | Interleukin-12 | 1 | 2013 | 121 | 0.100 |
Why?
| | Logistic Models | 5 | 2017 | 2064 | 0.100 |
Why?
| | Atherosclerosis | 1 | 2017 | 415 | 0.100 |
Why?
| | Informed Consent | 1 | 2013 | 170 | 0.100 |
Why?
| | Transcription, Genetic | 2 | 2010 | 1458 | 0.100 |
Why?
| | Cell Survival | 1 | 2015 | 1122 | 0.100 |
Why?
| | Lymphatic Vessels | 1 | 2012 | 64 | 0.090 |
Why?
| | Neuregulin-1 | 1 | 2012 | 46 | 0.090 |
Why?
| | Vital Capacity | 1 | 2013 | 309 | 0.090 |
Why?
| | Acute Disease | 2 | 2025 | 1008 | 0.090 |
Why?
| | Pepsin A | 1 | 2011 | 19 | 0.090 |
Why?
| | Ubiquitin | 1 | 2012 | 67 | 0.090 |
Why?
| | Chemokine CXCL12 | 1 | 2012 | 80 | 0.090 |
Why?
| | Serotonin | 1 | 2014 | 324 | 0.090 |
Why?
| | Lipid Peroxidation | 1 | 2012 | 152 | 0.090 |
Why?
| | Respiratory Aspiration | 1 | 2011 | 31 | 0.090 |
Why?
| | Phytotherapy | 1 | 2012 | 80 | 0.090 |
Why?
| | Magnetic Resonance Imaging | 2 | 2021 | 3722 | 0.090 |
Why?
| | Capillaries | 2 | 2009 | 108 | 0.090 |
Why?
| | Respiratory Function Tests | 1 | 2013 | 596 | 0.090 |
Why?
| | Prospective Studies | 6 | 2021 | 7598 | 0.090 |
Why?
| | Enzyme-Linked Immunosorbent Assay | 2 | 2012 | 849 | 0.090 |
Why?
| | Feasibility Studies | 2 | 2025 | 950 | 0.090 |
Why?
| | MicroRNAs | 1 | 2017 | 704 | 0.090 |
Why?
| | Genetic Testing | 1 | 2013 | 453 | 0.090 |
Why?
| | Night Care | 1 | 2010 | 4 | 0.090 |
Why?
| | After-Hours Care | 1 | 2010 | 15 | 0.080 |
Why?
| | Research Design | 2 | 2011 | 1116 | 0.080 |
Why?
| | Cell- and Tissue-Based Therapy | 1 | 2011 | 82 | 0.080 |
Why?
| | Collagen | 1 | 2012 | 447 | 0.080 |
Why?
| | Nervous System Diseases | 1 | 2013 | 265 | 0.080 |
Why?
| | Awards and Prizes | 1 | 2011 | 68 | 0.080 |
Why?
| | ROC Curve | 2 | 2017 | 547 | 0.080 |
Why?
| | Organizational Culture | 1 | 2011 | 145 | 0.080 |
Why?
| | Cell Differentiation | 2 | 2015 | 1979 | 0.080 |
Why?
| | Colony-Forming Units Assay | 1 | 2009 | 91 | 0.080 |
Why?
| | Autoantibodies | 1 | 2017 | 1501 | 0.080 |
Why?
| | Colorado | 5 | 2024 | 4521 | 0.080 |
Why?
| | Microbiota | 1 | 2017 | 763 | 0.080 |
Why?
| | Practice Guidelines as Topic | 1 | 2017 | 1580 | 0.080 |
Why?
| | Peer Group | 1 | 2011 | 244 | 0.080 |
Why?
| | Gastroesophageal Reflux | 1 | 2011 | 235 | 0.080 |
Why?
| | Program Development | 1 | 2011 | 366 | 0.080 |
Why?
| | Mice | 7 | 2022 | 17843 | 0.080 |
Why?
| | Thyrotoxicosis | 1 | 2008 | 9 | 0.080 |
Why?
| | Bayes Theorem | 2 | 2022 | 407 | 0.070 |
Why?
| | Technetium Tc 99m Pentetate | 1 | 2008 | 7 | 0.070 |
Why?
| | Lung Transplantation | 1 | 2011 | 309 | 0.070 |
Why?
| | Mice, Inbred C57BL | 5 | 2021 | 5792 | 0.070 |
Why?
| | Computers | 1 | 2008 | 68 | 0.070 |
Why?
| | Focus Groups | 1 | 2011 | 512 | 0.070 |
Why?
| | Hypertension, Pulmonary | 2 | 2011 | 1903 | 0.070 |
Why?
| | Radionuclide Imaging | 1 | 2008 | 119 | 0.070 |
Why?
| | Half-Life | 1 | 2008 | 166 | 0.070 |
Why?
| | Chest Pain | 1 | 2008 | 91 | 0.070 |
Why?
| | Quality Assurance, Health Care | 1 | 2010 | 324 | 0.070 |
Why?
| | Burn Units | 2 | 2022 | 48 | 0.070 |
Why?
| | Dose-Response Relationship, Drug | 3 | 2019 | 2066 | 0.070 |
Why?
| | Radiopharmaceuticals | 1 | 2008 | 178 | 0.070 |
Why?
| | Schools | 1 | 2011 | 465 | 0.070 |
Why?
| | Myeloid Cells | 1 | 2008 | 146 | 0.070 |
Why?
| | Multicenter Studies as Topic | 2 | 2022 | 308 | 0.070 |
Why?
| | Tissue Inhibitor of Metalloproteinase-1 | 1 | 2007 | 26 | 0.070 |
Why?
| | Cocaine-Related Disorders | 1 | 2008 | 113 | 0.070 |
Why?
| | Indicators and Reagents | 1 | 2007 | 109 | 0.070 |
Why?
| | Georgia | 2 | 2004 | 84 | 0.070 |
Why?
| | Respiration Disorders | 1 | 2007 | 77 | 0.070 |
Why?
| | Staphylococcus aureus | 1 | 2011 | 452 | 0.070 |
Why?
| | Cell Separation | 3 | 2016 | 320 | 0.070 |
Why?
| | Sex Factors | 1 | 2013 | 2074 | 0.070 |
Why?
| | Patient Readmission | 3 | 2019 | 696 | 0.070 |
Why?
| | Body Fluids | 1 | 2007 | 66 | 0.070 |
Why?
| | NIH 3T3 Cells | 1 | 2007 | 144 | 0.070 |
Why?
| | Program Evaluation | 1 | 2011 | 892 | 0.070 |
Why?
| | Pulmonary Artery | 2 | 2013 | 1083 | 0.070 |
Why?
| | Thrombocytopenia | 2 | 2019 | 199 | 0.070 |
Why?
| | Stem Cell Transplantation | 1 | 2008 | 177 | 0.070 |
Why?
| | Nursing Staff, Hospital | 1 | 2009 | 154 | 0.070 |
Why?
| | Matrix Metalloproteinases | 1 | 2007 | 94 | 0.060 |
Why?
| | Cross-Sectional Studies | 4 | 2022 | 5427 | 0.060 |
Why?
| | Lung Diseases, Interstitial | 1 | 2012 | 634 | 0.060 |
Why?
| | Propensity Score | 2 | 2017 | 288 | 0.060 |
Why?
| | Pneumonia, Bacterial | 1 | 2006 | 117 | 0.060 |
Why?
| | Louisiana | 1 | 2024 | 29 | 0.060 |
Why?
| | T-Lymphocytes | 1 | 2013 | 1999 | 0.060 |
Why?
| | Adolescent | 6 | 2022 | 21555 | 0.060 |
Why?
| | Observation | 1 | 2004 | 52 | 0.050 |
Why?
| | Respiration | 1 | 2025 | 198 | 0.050 |
Why?
| | Hemorrhage | 2 | 2019 | 723 | 0.050 |
Why?
| | Fatty Acids, Volatile | 1 | 2024 | 58 | 0.050 |
Why?
| | Dimercaprol | 1 | 2023 | 6 | 0.050 |
Why?
| | Neoplasms | 1 | 2018 | 2666 | 0.050 |
Why?
| | Hand Strength | 1 | 2024 | 122 | 0.050 |
Why?
| | Hydroxyethyl Starch Derivatives | 1 | 2003 | 9 | 0.050 |
Why?
| | Databases, Factual | 2 | 2019 | 1351 | 0.050 |
Why?
| | Time Factors | 4 | 2018 | 6817 | 0.050 |
Why?
| | Surveys and Questionnaires | 2 | 2022 | 5772 | 0.050 |
Why?
| | Analgesia | 1 | 2024 | 110 | 0.050 |
Why?
| | Body Surface Area | 1 | 2022 | 34 | 0.050 |
Why?
| | Nutritional Status | 1 | 2005 | 344 | 0.050 |
Why?
| | Adaptive Clinical Trials as Topic | 1 | 2022 | 22 | 0.050 |
Why?
| | Clinical Trials, Phase II as Topic | 1 | 2022 | 75 | 0.050 |
Why?
| | Phosphoric Monoester Hydrolases | 1 | 2022 | 55 | 0.050 |
Why?
| | rhoA GTP-Binding Protein | 2 | 2014 | 87 | 0.050 |
Why?
| | Vasopressins | 1 | 2022 | 64 | 0.050 |
Why?
| | Single-Cell Analysis | 1 | 2024 | 309 | 0.050 |
Why?
| | Receptors, Polymeric Immunoglobulin | 1 | 2021 | 2 | 0.050 |
Why?
| | North America | 1 | 2022 | 313 | 0.050 |
Why?
| | rho-Associated Kinases | 2 | 2014 | 85 | 0.050 |
Why?
| | Transcytosis | 1 | 2021 | 7 | 0.050 |
Why?
| | Vasoconstrictor Agents | 1 | 2022 | 138 | 0.040 |
Why?
| | Blood Alcohol Content | 1 | 2021 | 5 | 0.040 |
Why?
| | Norepinephrine | 1 | 2022 | 212 | 0.040 |
Why?
| | Naltrexone | 1 | 2022 | 97 | 0.040 |
Why?
| | Hedgehog Proteins | 1 | 2022 | 197 | 0.040 |
Why?
| | Bleomycin | 1 | 2022 | 247 | 0.040 |
Why?
| | Mice, Knockout | 2 | 2021 | 3020 | 0.040 |
Why?
| | Cilia | 1 | 2022 | 186 | 0.040 |
Why?
| | Ligands | 1 | 2023 | 665 | 0.040 |
Why?
| | Containment of Biohazards | 1 | 2020 | 12 | 0.040 |
Why?
| | Stress Disorders, Post-Traumatic | 1 | 2009 | 854 | 0.040 |
Why?
| | Recombinant Proteins | 2 | 2015 | 1357 | 0.040 |
Why?
| | Rats | 2 | 2017 | 5676 | 0.040 |
Why?
| | Intersectoral Collaboration | 1 | 2020 | 60 | 0.040 |
Why?
| | Medical Oncology | 1 | 2022 | 290 | 0.040 |
Why?
| | Protein Transport | 1 | 2021 | 443 | 0.040 |
Why?
| | Prognosis | 3 | 2013 | 4031 | 0.040 |
Why?
| | Incidence | 2 | 2003 | 2792 | 0.040 |
Why?
| | Pharmacoepidemiology | 1 | 2019 | 19 | 0.040 |
Why?
| | Chronic Disease | 3 | 2015 | 1790 | 0.040 |
Why?
| | Administration, Intravenous | 1 | 2019 | 154 | 0.040 |
Why?
| | Fellowships and Scholarships | 1 | 2022 | 306 | 0.040 |
Why?
| | Qualitative Research | 1 | 2025 | 1361 | 0.040 |
Why?
| | Hospitals, Rural | 1 | 2018 | 39 | 0.040 |
Why?
| | Coronary Circulation | 1 | 2018 | 141 | 0.040 |
Why?
| | Illinois | 1 | 2017 | 43 | 0.040 |
Why?
| | Leadership | 1 | 2022 | 382 | 0.040 |
Why?
| | Hospital Charges | 1 | 2017 | 43 | 0.040 |
Why?
| | RNA Transport | 1 | 2017 | 23 | 0.030 |
Why?
| | Comparative Effectiveness Research | 1 | 2018 | 152 | 0.030 |
Why?
| | Hospitals, Urban | 1 | 2018 | 135 | 0.030 |
Why?
| | Adaptation, Psychological | 1 | 2022 | 653 | 0.030 |
Why?
| | Poly(ADP-ribose) Polymerases | 1 | 2017 | 99 | 0.030 |
Why?
| | Administration, Oral | 1 | 2019 | 814 | 0.030 |
Why?
| | Algorithms | 1 | 2024 | 1702 | 0.030 |
Why?
| | Disease-Free Survival | 1 | 2018 | 690 | 0.030 |
Why?
| | Health Knowledge, Attitudes, Practice | 1 | 2025 | 1332 | 0.030 |
Why?
| | Dried Blood Spot Testing | 1 | 2017 | 103 | 0.030 |
Why?
| | Venous Thrombosis | 1 | 2019 | 187 | 0.030 |
Why?
| | Longitudinal Studies | 1 | 2024 | 2857 | 0.030 |
Why?
| | Gene Knockdown Techniques | 1 | 2017 | 329 | 0.030 |
Why?
| | Sex Distribution | 1 | 2017 | 378 | 0.030 |
Why?
| | Postoperative Complications | 1 | 2008 | 2641 | 0.030 |
Why?
| | RNA Precursors | 1 | 2017 | 153 | 0.030 |
Why?
| | Pulmonary Surfactant-Associated Protein D | 1 | 2016 | 35 | 0.030 |
Why?
| | Gene Rearrangement, delta-Chain T-Cell Antigen Receptor | 1 | 2015 | 4 | 0.030 |
Why?
| | Gene Rearrangement, gamma-Chain T-Cell Antigen Receptor | 1 | 2015 | 8 | 0.030 |
Why?
| | Capillary Leak Syndrome | 1 | 2015 | 12 | 0.030 |
Why?
| | Cell Communication | 1 | 2017 | 313 | 0.030 |
Why?
| | Capillary Permeability | 1 | 2016 | 144 | 0.030 |
Why?
| | Diet, High-Fat | 1 | 2017 | 248 | 0.030 |
Why?
| | Chromatography, Liquid | 1 | 2017 | 433 | 0.030 |
Why?
| | Cause of Death | 1 | 2017 | 431 | 0.030 |
Why?
| | Risk | 1 | 2018 | 905 | 0.030 |
Why?
| | Interferon-alpha | 1 | 2016 | 198 | 0.030 |
Why?
| | Linear Models | 1 | 2017 | 851 | 0.030 |
Why?
| | Ventricular Function, Left | 1 | 2018 | 540 | 0.030 |
Why?
| | RNA, Ribosomal, 16S | 1 | 2017 | 544 | 0.030 |
Why?
| | Coculture Techniques | 1 | 2015 | 240 | 0.030 |
Why?
| | Delivery of Health Care | 1 | 2022 | 948 | 0.030 |
Why?
| | Cognition | 1 | 2023 | 1192 | 0.030 |
Why?
| | Interleukin-4 | 1 | 2015 | 217 | 0.030 |
Why?
| | Sequence Analysis, DNA | 1 | 2017 | 812 | 0.030 |
Why?
| | Predictive Value of Tests | 1 | 2019 | 2039 | 0.030 |
Why?
| | Kaplan-Meier Estimate | 1 | 2016 | 892 | 0.030 |
Why?
| | Gastrointestinal Tract | 1 | 2016 | 194 | 0.030 |
Why?
| | Mental Competency | 1 | 2013 | 26 | 0.030 |
Why?
| | Odds Ratio | 1 | 2016 | 1063 | 0.030 |
Why?
| | Catheterization, Swan-Ganz | 1 | 2013 | 9 | 0.030 |
Why?
| | Phylogeny | 1 | 2017 | 898 | 0.030 |
Why?
| | Confidence Intervals | 1 | 2014 | 328 | 0.030 |
Why?
| | Ventilator Weaning | 1 | 2013 | 36 | 0.030 |
Why?
| | Survival Analysis | 1 | 2016 | 1320 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor D | 1 | 2012 | 13 | 0.030 |
Why?
| | Tidal Volume | 1 | 2013 | 86 | 0.030 |
Why?
| | Vascular Endothelial Growth Factor C | 1 | 2012 | 17 | 0.030 |
Why?
| | Lymphangiogenesis | 1 | 2012 | 27 | 0.030 |
Why?
| | Thymus Gland | 1 | 2014 | 313 | 0.020 |
Why?
| | Biological Transport | 1 | 2014 | 416 | 0.020 |
Why?
| | Fibrosis | 1 | 2015 | 552 | 0.020 |
Why?
| | National Institutes of Health (U.S.) | 1 | 2012 | 129 | 0.020 |
Why?
| | Fluid Therapy | 1 | 2013 | 147 | 0.020 |
Why?
| | Lipid Metabolism | 1 | 2015 | 511 | 0.020 |
Why?
| | Mass Spectrometry | 1 | 2015 | 741 | 0.020 |
Why?
| | Observer Variation | 1 | 2012 | 347 | 0.020 |
Why?
| | Nanoparticles | 1 | 2017 | 484 | 0.020 |
Why?
| | Healthcare Disparities | 1 | 2018 | 651 | 0.020 |
Why?
| | Bronchiolitis Obliterans | 1 | 2011 | 69 | 0.020 |
Why?
| | Protein Binding | 1 | 2017 | 2229 | 0.020 |
Why?
| | Rats, Sprague-Dawley | 1 | 2017 | 2501 | 0.020 |
Why?
| | Microbial Viability | 1 | 2011 | 91 | 0.020 |
Why?
| | Research Personnel | 1 | 2012 | 170 | 0.020 |
Why?
| | Infusions, Intravenous | 1 | 2012 | 411 | 0.020 |
Why?
| | Extracellular Matrix | 1 | 2015 | 528 | 0.020 |
Why?
| | Superoxides | 1 | 2011 | 202 | 0.020 |
Why?
| | World Health Organization | 1 | 2011 | 122 | 0.020 |
Why?
| | Proteomics | 1 | 2017 | 1113 | 0.020 |
Why?
| | Immunomodulation | 1 | 2011 | 98 | 0.020 |
Why?
| | p38 Mitogen-Activated Protein Kinases | 1 | 2011 | 283 | 0.020 |
Why?
| | Radiography | 1 | 2012 | 834 | 0.020 |
Why?
| | Viruses | 1 | 2011 | 112 | 0.020 |
Why?
| | Species Specificity | 1 | 2011 | 593 | 0.020 |
Why?
| | Injury Severity Score | 1 | 2012 | 525 | 0.020 |
Why?
| | rho GTP-Binding Proteins | 1 | 2010 | 61 | 0.020 |
Why?
| | Amides | 1 | 2010 | 93 | 0.020 |
Why?
| | Autoimmune Diseases | 1 | 2014 | 459 | 0.020 |
Why?
| | Blood Pressure | 1 | 2017 | 1776 | 0.020 |
Why?
| | Metabolomics | 1 | 2015 | 679 | 0.020 |
Why?
| | Receptor, ErbB-2 | 1 | 2012 | 342 | 0.020 |
Why?
| | Cell Death | 1 | 2011 | 370 | 0.020 |
Why?
| | Lung Compliance | 1 | 2009 | 49 | 0.020 |
Why?
| | Endoscopy, Gastrointestinal | 1 | 2011 | 227 | 0.020 |
Why?
| | Phosphorylation | 1 | 2014 | 1762 | 0.020 |
Why?
| | Gene Expression Profiling | 1 | 2016 | 1770 | 0.020 |
Why?
| | Physician-Nurse Relations | 1 | 2009 | 17 | 0.020 |
Why?
| | Biopsy | 1 | 2012 | 1132 | 0.020 |
Why?
| | AC133 Antigen | 1 | 2008 | 20 | 0.020 |
Why?
| | Leisure Activities | 1 | 2009 | 32 | 0.020 |
Why?
| | Cell Fusion | 1 | 2008 | 51 | 0.020 |
Why?
| | Giant Cells | 1 | 2008 | 24 | 0.020 |
Why?
| | Triiodothyronine | 1 | 2008 | 43 | 0.020 |
Why?
| | Mitochondria | 1 | 2015 | 947 | 0.020 |
Why?
| | Leukocyte Common Antigens | 1 | 2008 | 87 | 0.020 |
Why?
| | Thyroxine | 1 | 2008 | 62 | 0.020 |
Why?
| | Nurse Administrators | 1 | 2009 | 44 | 0.020 |
Why?
| | Outpatient Clinics, Hospital | 1 | 2009 | 83 | 0.020 |
Why?
| | Drug Administration Schedule | 1 | 2010 | 784 | 0.020 |
Why?
| | Osteocytes | 1 | 2008 | 28 | 0.020 |
Why?
| | Breath Tests | 1 | 2007 | 87 | 0.020 |
Why?
| | Clone Cells | 1 | 2008 | 266 | 0.020 |
Why?
| | Databases as Topic | 1 | 2007 | 66 | 0.020 |
Why?
| | Curriculum | 1 | 2014 | 980 | 0.020 |
Why?
| | Child | 2 | 2022 | 22037 | 0.020 |
Why?
| | Laparoscopy | 1 | 2011 | 464 | 0.020 |
Why?
| | Social Environment | 1 | 2009 | 305 | 0.020 |
Why?
| | Cell Movement | 1 | 2011 | 972 | 0.020 |
Why?
| | Health Surveys | 1 | 2009 | 520 | 0.020 |
Why?
| | Glycoproteins | 1 | 2008 | 345 | 0.020 |
Why?
| | Job Satisfaction | 1 | 2009 | 216 | 0.020 |
Why?
| | Models, Biological | 1 | 2014 | 1775 | 0.020 |
Why?
| | Hydrogen-Ion Concentration | 1 | 2007 | 566 | 0.020 |
Why?
| | Adipocytes | 1 | 2008 | 215 | 0.020 |
Why?
| | Trauma Centers | 1 | 2009 | 422 | 0.020 |
Why?
| | Hydrogen Peroxide | 1 | 2007 | 320 | 0.020 |
Why?
| | Randomized Controlled Trials as Topic | 1 | 2012 | 1465 | 0.020 |
Why?
| | Cell Lineage | 1 | 2008 | 346 | 0.020 |
Why?
| | Chondrocytes | 1 | 2008 | 213 | 0.020 |
Why?
| | Antigens, CD | 1 | 2008 | 524 | 0.020 |
Why?
| | Telomerase | 1 | 2008 | 250 | 0.010 |
Why?
| | Diagnosis, Differential | 1 | 2008 | 1486 | 0.010 |
Why?
| | Health Care Costs | 1 | 2007 | 387 | 0.010 |
Why?
| | France | 1 | 2003 | 33 | 0.010 |
Why?
| | Contraindications | 1 | 2003 | 90 | 0.010 |
Why?
| | Washington | 1 | 2003 | 154 | 0.010 |
Why?
| | Peptides | 1 | 2008 | 986 | 0.010 |
Why?
| | Cardiac Output | 1 | 2003 | 164 | 0.010 |
Why?
| | Cell Proliferation | 1 | 2008 | 2482 | 0.010 |
Why?
| | Analysis of Variance | 1 | 2003 | 1324 | 0.010 |
Why?
|
|
Burnham's Networks
Click the "See All" links for more information and interactive visualizations!
Concepts  Derived automatically from this person's publications. _
Co-Authors  People in Profiles who have published with this person. _
Similar People  People who share similar concepts with this person. _
Same Department
People who are also in this person's primary department.
Physical Neighbors  People whose addresses are nearby this person. _
|